{
    "clinical_study": {
        "@rank": "97513", 
        "acronym": "PAP", 
        "arm_group": [
            {
                "arm_group_label": "D1", 
                "arm_group_type": "Experimental", 
                "description": "Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (\u00b13 day).\nIf the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months\uff0cthen rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption\u226525% , and /or the PaO2 elevated by 5 mm Hg."
            }, 
            {
                "arm_group_label": "D2", 
                "arm_group_type": "Experimental", 
                "description": "Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (\u00b13 day).\nWhen the treatment is ineffective, and anti-GM-CSF antibody titers level \u22651:1000\uff0cthe dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
            }, 
            {
                "arm_group_label": "D3", 
                "arm_group_type": "Experimental", 
                "description": "Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (\u00b13 day).\nWhen the treatment is ineffective, and anti-GM-CSF antibody titers level \u22651:1000\uff0cthe dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
            }, 
            {
                "arm_group_label": "D4", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (\u00b13 day).\nWhen the treatment is ineffective, and anti-GM-CSF antibody titers level \uff1c1:1000\uff0cthe patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish an efficient and economic treatment scheme by\n      evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of\n      similar injection after whole lung lavage , in patients with PAP."
        }, 
        "brief_title": "Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Alveolar Proteinosis", 
        "condition_browse": {
            "mesh_term": "Pulmonary Alveolar Proteinosis"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to establish an efficient and economic treatment scheme by\n      evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of\n      similar injection after whole lung lavage , in patients with PAP. During the observation,\n      study visits will occur at the end of each month. During the 1-year follow-up period which\n      is lasting 6 months after the treatment, all participants will be required to check the\n      various efficacy indicators."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed PAP patients\n\n          -  Aged 17-80\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Secondary PAP\n\n          -  Received whole lung lavage therapy within 4 weeks before enrollment\n\n          -  Received previous GM-CSF therapy within 6 months before enrollment\n\n          -  WBC\u226512,000/ul\n\n          -  fever\u226538\u2103\n\n          -  Severe edema, severe liver, kidney, lung and cardiovascular disease.\n\n          -  Pregnant\uff0cplanning to get pregnant or nursing\n\n          -  Inability to express the subjective discomfort\n\n          -  Serious drug allergy history, E.coli preparation or rhGM-CSF serious allergy history"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983657", 
            "org_study_id": "20120401"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "D1", 
                    "D2", 
                    "D3", 
                    "D4"
                ], 
                "description": "GM-CSF will be given subcutaneously according to the rule in different groups.", 
                "intervention_name": "rhGM-CSF", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TOPLEUCON", 
                    "GM-CSF", 
                    "Recombinant Granulocyte Macrophage-Colony Stimulating Factor", 
                    "Granulocyte Macrophage-Colony Stimulating Factor"
                ]
            }, 
            {
                "arm_group_label": "D4", 
                "description": "using double lumen endotracheal tube (DLT) to selectively lavage one lung", 
                "intervention_name": "Whole Lung Lavage(WLL)", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Whole Lung Lavage", 
                    "WLL"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary", 
            "Pulmonary Alveolar Proteinosis", 
            "PAP"
        ], 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "contact": {
                "email": "liw2013@126.com", 
                "last_name": "Huiping Li, Doctor", 
                "phone": "86-13817389991"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200433"
                }, 
                "name": "Shanghai Pulmonary Hospital"
            }, 
            "investigator": {
                "last_name": "Huiping Li, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.", 
        "overall_contact": {
            "email": "liw2013@126.com", 
            "last_name": "Huiping Li, Dr", 
            "phone": "86-13817389991"
        }, 
        "overall_official": {
            "affiliation": "Shanghai Pulmonary Hospital, Shanghai, China", 
            "last_name": "Huiping Li, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvements in double pulmonary diffuse lesions \uff08Chest  CT score \uff09", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983657"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Pulmonary Hospital, Shanghai, China", 
            "investigator_full_name": "Huiping Li", 
            "investigator_title": "Professor,Chief of Dept. of Respiratory Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical symptoms observation: shod of breath, cough (according to  each score standard\uff09", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Granulocyte Macrophage Colony Stimulating Factor(GM-CSF) Antibody titer change", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Pulmonary function tests include residual volume/total lung capacity(RV/TLC), forced vital capacity(FVC), forced expiratory volume in one second/forced vital capacity(FEV1/FVC), diffusing capacity of carbon monoxide(DLCO).", 
                "measure": "Improvements in pulmonary function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Improvements in arterial blood gas, including alveolar-arterial oxygen difference(A-aDO2), partial pressure of oxygen(PaO2), partial pressure of carbon dioxide in artery(PaCO2), arterial oxygen saturation(SaO2).", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Shanghai Pulmonary Hospital, Shanghai, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Pulmonary Hospital, Shanghai, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}